The pattern of constitutive and cycle-dependent integrins in normal endometrium has recently been established, suggesting a role for cell adhesion molecules in endometrial receptivity and implantation. Currently few, if any, models exist for the study of human endometrial integrins and their role in establishment of the receptive endometrial phenotype. The Ishikawa cell line maintains functional estrogen receptors and progesterone receptors. The progesterone receptors in these cells are inducible by priming with estradiol and down-regulated by treatment with progesterone. In the present study, the pattern of integrin expression in this well differentiated endometrial cell line is compared to that in normal endometrial epithelium using immunohistochemistry and flow cytometry and is confirmed by immunoprecipitation, Western immunoblot, and PCR. Like normal endometrial epithelium, Ishikawa cells maintain constitutive expression of ␣ 2 ␤ 1 , ␣ 3 ␤ 1 , ␣ 6 ␤ 4 . PCR demonstrates the expected size fragments of each, although evidence for alternatively spliced forms of the ␣ 2 -subunit was noted. Progesterone treatment of estradiolprimed cells resulted in increased expression of the ␣ 1 ␤ 1 collagenlaminin receptor and suppression of the ␣ v ␤ 3 vitronectin receptor, two of the cycle-dependent integrins expressed by normal endometrial epithelium. These data support the use of Ishikawa cells as an excellent model to study the regulation endometrial integrins and advance our understanding of hormonally mediated events surrounding implantation. (J Clin Endocrinol Metab 82: 136 -142, 1997) 
T HE HUMAN endometrium is a dynamically active tissue in the cycling reproductive-aged woman. As in other species (1) , the human endometrium undergoes spatial and temporal changes that culminate in a defined period of uterine receptivity toward embryonic implantation (2) . Although the mechanism for the establishment of receptivity remains poorly understood, the timing of the "window of implantation" in the human appears to be confined to postovulatory days 6 -10, based on morphological (3) studies and data from embryo transfers in hormonally prepared recipients in the in vitro fertilization setting (4) . We have suggested that defects in uterine receptivity may account for a significant proportion of failed in vitro fertilization attempts (5) as well as the underlying cause in many couples with unexplained infertility (6) , endometriosis (7) , and luteal phase defect (8) , supported by an increasing amount of clinical data (9) . Few good models currently exist, however, to study the role of specific endometrial proteins in human implantation.
Although numerous endometrial cancer cell lines have been established and characterized, the Ishikawa cell line appears to be an excellent model to study normal endometrial epithelium. These cells, first described by Nashida et al. (10) , maintain estrogen (ER) and progesterone (P) receptors (PR) (10, 11) . The PR in these cells is inducible by estrogen and suppressible by P and is immunologically and biochemically similar to PR in normal endometrium (12, 13) . Furthermore, this cell line expresses many of the same enzymes and structural proteins found in normal endometrium (14 -18) . We recently demonstrated the functionality of both ER and PR in Ishikawa cells (13) by the induction ␣ 1 ␤ 1 , a Presponsive integrin family normally expressed on glandular epithelium only during the secretory phase of the menstrual cycle (8, 19) .
In the present study we further characterize Ishikawa cells as a model for the study of normal endometrial epithelium, initiating a general survey of integrins in this cell line. This class of cell adhesion molecules has been implicated in normal cellular phenotype and were measured to judge the similarities between Ishikawa cells and normal endometrial epithelium. Furthermore, the role of cycle-dependent integrin expression in reproduction is becoming increasingly relevant to the process of implantation and the functioning of the endometrium (20 -22) . The study of the regulation of hormone-dependent events in a suitable cell model of the endometrium will greatly advance our understanding of the factors that favor the establishment of uterine receptivity toward embryo implantation in the human.
Materials and Methods

Cell lines
Ishikawa cells were grown and maintained in MEM containing 5% (vol/vol) nonstripped FCS, 200 nmol/L l-glutamine, and 5% gentamicin. The cells were maintained in 150-cm 2 flasks (Costar, Cambridge, MA) in humidified chambers containing 95% air-5% CO 2 at a temperature of 37 C. At near confluency, the cells were treated with culture medium with or without added steroid hormones. The time of exposure varied from 1-4 days. The experimental medium was composed of phenol red-free MEM-Ham's F-12 (1:1, vol/vol) plus 5% charcoalstripped FCS. The hormones were added from a 1000-fold concentrated stock in 100% ethanol and 17␤-estradiol (E 2 ; 10 Ϫ8 mol/L) with or without added P (10 Ϫ6 mol/L). In certain experiments, the antiprogestin RU-486 (10 Ϫ6 mol/L) was added to cells treated with E 2 plus P.
Immunofluorescence and flow cytometry
Immunoperoxidase staining was performed using the specific monoclonal antibodies listed in Table 1 , as previously described (23) (24) (25) (26) (27) (28) (29) (30) (31) . Ishikawa cells were grown to confluence on glass coverslips in 12-well plates (Corning Costar Corp., Cambridge, MA). After no treatment, or treatment with E 2 (10 Ϫ8 mol/L) or E 2 plus P (10 Ϫ6 mol/L), the coverslips were lightly fixed in 3.7% formaldehyde in phosphate-buffered saline (PBS; pH 7.4) for 10 min at room temperature, followed by a 5-min PBS wash, cold methanol for 4 min, and cold acetone for 1 min before a final PBS wash for 5 min.
Immunofluorescence was performed on coverslips containing the fixed Ishikawa cells using a Vectastain kit (Vector Laboratories, Burlingame, CA). After incubation with blocking antibody for 15 min at room temperature (1:100 dilution of nonimmune mouse serum), primary antibody was applied for 1 h. After a 5-min PBS rinse, biotinylated goat antimouse IgG conjugated to fluorescein isothiocyanate (1:100 dilution) was placed on the coverslips and incubated for 30 min at room temperature, followed by two more 5-min PBS washes. Binding was visualized by fluorescent microscopy. Photomicrographs were made with Kodak 3200 ASA film (Eastman Kodak, Rochester, NY).
For flow cytometry, Ishikawa cells were detached from culture flasks using trypsin-ethylenediamine tetraacetate for 5-10 min (Life Technologies, Grand Island, NY), then neutralized with an equal volume of 5% FCS and spun at 300 ϫ g for 10 min; the supernatant was discarded, and cells were resuspended in a volume of PBS, pH 7.4, to yield a concentration of 100,000 cells/100 L. Then, 500-L aliquots were added to individual polypropylene tubes, spun down, resuspended in 300 L PBS-4% BSA containing primary mouse antihuman antibody, and incubated for 60 min at 4 C on a shaker. The sample was spun for 10 min at 300 ϫ g, followed by a wash with 500 L PBS-4% BSA, and again centrifuged at 300 ϫ g for 10 min. The pellet was resuspended in 300 L PBS-4% BSA and 1:100 diluted FITC-conjugated horse antimouse IgG and incubated for 30 min at 4 C on a shaker in the dark. Two additional wash/spin steps were performed, then the final pellet was resuspended in 500 L PBS-0.02% propidium iodide (Sigma Chemical Co., St. Louis, MO). The instrumentation used for flow cytometry consisted of a FACScan linked to a Consort 32 computer with Lysis II software, which was used for both data acquisition and data analysis (Becton Dickinson, San Jose, CA). Cells analyzed by flow cytometry were excited by an argon laser emitting 15 mW at 488 nm. Propidium iodide-stained cells were gated out during data collection. Green fluorescence of the remaining live cells was collected by photomultiplier through a 530/30 nm bandpass filter. A logarithmic amplifier was used to compress the resulting fluorescence signal for storage and display on a 4-decade log scale by Lysis II. Subsequent analysis of green fluorescence was used to determine the relative median fluorescence of each sample. This value was defined as follows. Cells labeled with fluorescent second antibody in the absence of primary antibody were used to obtain the arithmetic median of background fluorescence for each set of samples. This value was subtracted from the median fluorescence of each of the other samples in the set. The resulting adjusted median for each treatment condition was then divided by the adjusted median of its control to obtain the relative median fluorescence of the stimulated sample as a multiple of the control.
PCR
Messenger ribonucleic acid was obtained from Ishikawa cells grown under standard conditions without hormone treatment, using oligo(deoxythymidine) chromatography and complementary DNA (cDNA) produced using a reverse transcriptase kit (Invitrogen, San Diego, CA). Single stranded cDNA was synthesized for amplification using 50 pmol oligonucleotide primers 16 -23 bp in length in a 50-L reaction volume (Invitrogen, San Diego, CA). PCR conditions were: denaturation at 95 C for 1 min, annealing at 60 C for 1.5 min, extension at 72 C for 3 min, followed by the second cycle with extension at 72 C for 10 min. Oligomer primers for PCR for the ␣ 1 -, ␣ 2 -, ␣ 3 -, ␣ 4 -, ␣ 5 -, ␣ 6 -, and ␤ 4 -subunits and the expected sizes of the PCR products are shown in Table 2 . Products of PCR were separated on 1% agarose gel electrophoresis containing ethidium bromide and visualized and photographed on a UV light box. The sizes of the separated products were determined by concomitant separation of size markers of DNA.
Immunoprecipitation and Western blot analysis
Cell membrane lysates were obtained from Ishikawa cells treated with no hormones, with E 2 (10 Ϫ8 mol/L) with or without P (10 Ϫ6 mol/L), or with E 2 plus P plus RU486 (10 Ϫ6 mol/L). Before preparation of membrane protein lysates, cells were incubated for 1 h with 100 L biotin (10 g/L in PBS; Sigma Chemical Co.) and rinsed three times. Membrane extracts were prepared by lysis with Nonidet P-40-containing buffer as previously described (8) . The membrane extract was precleared with protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden). Using specific monoclonal antibodies, membrane extract was incubated with primary antibody and rocked for 1 h at 4 C before precipitation with protein A-Sepharose. After five washes, samples were extracted in 1-fold concentrated sample buffer and analyzed by 7.5% SDS-PAGE under nonreducing conditions. Gels were then transferred to nylon membrane. The membrane was blocked with 5% milk (from dehydrate) in trisbuffered saline plus 0.05% tween 20, pH 7.5 incubated with goat antimouse IgG (1:100), washed, and incubated in avidin conjugated to alkaline phosphatase (Dako, Carpenteria, CA) before incubation with ECL chemoluminescence reagent (Amersham, Arlington Heights, IL). Chemoluminescence was developed on x-ray film for 5-10 min before film development.
For Western blot of the ␤ 3 -integrin, membrane extract was prepared from Ishikawa cells that had been pretreated for 4 days with E 2 (10 Ϫ8 mol/L) or E 2 plus P (10 Ϫ6 mol/L) or in the presence of E 2 plus P plus equimolar RU-486 (10 Ϫ6 mol/L). The protein concentration was determined by the method of Lowry, and equal amounts of protein were added to 1-fold concentrated sample buffer and analyzed by 7.5% SDS-PAGE under nonreducing conditions as described above. The resulting blots were blocked as described and then incubated with SSA6 supernatant for 1 h at room temperature. The blots were incubated with goat antimouse IgG (1:100) and then developed as described for immunoprecipitation experiments.
Results
The well differentiated adenocarcinoma cell line, Ishikawa, maintains the same constitutive integrins previously noted in normal endometrial epithelium, namely ␣ 2 ␤ 1 , ␣ 3 ␤ 1 , and ␣ 6 ␤ 4 (8) . Each of these integrins serves as a receptor for either collagen or laminin, found in basement membranes.
As shown in Fig. 1 , using flow cytometry performed on Ishikawa cells shows that these cells expressed the collagen/ laminin receptors subunits ␣ 2 , ␣ 3 , ␣ 6 , and ␤ 4 compared to the negative control using no primary antibody (Fig. 1 ). These cells (in the absence of added hormones) expressed little if any ␣ 4 . Untreated Ishikawa cells expressed both subunits of the ␣ v ␤ 3 vitronectin receptor. This integrin has been shown to appear on normal endometrial epithelium at the time of implantation (8, 13, 23) . Photomicrographs of immunofluorescence confirms these findings (Fig. 2, B-H ), compared to negative controls ( Fig. 2A) . Note that the stromal integrin subunit ␣ 5 was not expressed in these cells (Fig. 2E) as previously reported in normal endometrial epithelium. The integrins expressed by Ishikawa cells appeared similar to normal integrin subunits based on the products of PCR. We observed the constitutively expressed epithelial integrin subunits ␣ 2 , ␣ 3 , ␣ 6 , and ␤ 4 messenger ribonucleic acid transcripts, each with the predicted size (Fig. 3, lanes 1-4 , respectively), although two smaller bands were also visible for the ␣ 2 -subunit, suggesting alternatively spliced forms may be expressed in this cell line, compared to the expected size based on the ␣ 2 cDNA (lane 6). The ␣ 5 -subunit was not detected in Ishikawa cells by PCR (lane 5).
Immunoprecipitation was initially performed on cells treated without added steroids (Fig. 4) . Under these conditions, Ishikawa cells express little ␣ 1 , but express the ␣ 2 ␤ 1 -and ␣ 3 ␤ 1 -integrins seen in normal endometrial epithelium (lanes 2 and 3) . The ␣ 4 ␤ 1 -and ␣ 5 ␤ 1 -integrins were not present in these cells (lanes 4 and 5). In contrast to the ␣ 1 -integrin subunit, which was barely detectable (lane 1), ␣ v ␤ 3 was strongly expressed (lanes 6 and 7, respectively).
To further study these phenomena of hormone-dependent integrin expression, we again performed flow cytometry studies. As shown in Fig. 5 , there was a clear induction of the ␣ 1 -subunit after treatment with E 2 plus P, but none with control medium or E 2 treatment alone (inset). With E 2 or P
FIG. 1. Flow cytometry of several epithelial integrins in Ishikawa cells. As described in Materials and
Methods, Ishikawa cells were specifically labeled with monoclonal antibodies against several integrin subunits normally found in human endometrial epithelium, and the number of cells stained was quantitated using flow cytometry. Compared to cells that were not exposed to antibody (Control), there was increased signal for the ␣ 2 -, ␣ 3 -, ␣ 6 -, and ␤ 4 -subunits in Ishikawa cells. Unlike secretory endometrial epithelium, there was no ␣ 4 -subunit detected. CAT GTG TAC CTG GGT G GGC TGG AGG CTT GAG 1100 ␣ 6 TGT TGC CAT CCT ACC GTC TTT AGA TAG GGG AGG AAA CAA AAC 692 ␤ 4 CCG GAT GCTGCT TAT TGA GAA TGA GGG TGG AGG ATG TGC TTA 414 treatment alone (bar graphs in Fig. 5) , there was little effect on ␣ 1 compared to the control. If cells were pretreated for prolonged periods with E 2 before P treatment for only 1 day, ␣ 1 levels were higher (fourth bar) than those after concomitant E 2 plus P treatment for 4 days (third bar). The positive effect of E 2 plus P was reversed by the addition of the antiprogestin RU-486. As shown in Figs. 2 and 4 , the ␣ v ␤ 3 -vitronectin receptor appeared to be expressed in these cells in the absence of hormone treatment. The expression of ␣ v ␤ 3 was reduced by E 2 treatment and further suppressed by E 2 plus P, as shown by flow cytometry (Fig. 6A) and Western blot analysis (Fig.  6B ). This suppression of ␣ v ␤ 3 was reversed by the addition of the antiprogestin, RU486. P treatment alone had little or no effect on ␤ 3 expression (data not shown).
Discussion
Recently, integrins have been identified as useful phenotypic markers of endometrial function and may play a role in the cascade of events leading to normal implantation (20, 21) . We and others recently described the pattern of expression of this family of cell adhesion molecules in the human endometrium (8, 19) . One integrin, the ␣ v ␤ 3 vitronectin receptor, is expressed on endometrial epithelial cells only at the opening of the implantation window, on postovulatory day 1-4, respectively) . No ␣ 5 transcript was noted in these cells (lane 5). The size of each product was as predicted (see Table 2 ), with the exception of ␣ 2 , which appears to contain alternatively spliced transcripts ranging from approximately 550 -900 bp compared to PCR performed from the full-length ␣ 2 containing plasmid (lane 6).
FIG. 2.
Photomicrographs of Ishikawa cells using immunofluorescence and specific monoclonal antibodies to several integrin subunits. As described in Materials and Methods and Table 1 , no staining was seen in the absence of antibody (Control; A). Specific staining was noted for ␣ 2 -subunit (B) and ␣ 3 -subunit (C), but not ␣ 4 -or ␣ 5 -subunit (D and E). The ␣ 6 antibody GoH3 yielded strong staining, thought to be ␣ 6 ␤ 4 (F), similar to normal endometrial epithelium. Note that the ␤ 4 -specific mAb also exhibits similar staining between cells (I). The ␣ v -specific antibody LM-142 and the ␣ v ␤ 3 -specific antibodies SSA6 or LM609 demonstrated positive staining in both focal contacts (G) and between cells (H).
(8).
It has subsequently been demonstrated that certain integrins may be useful markers of uterine receptivity, coexpressed only during the window of implantation (LH plus 6 to 10) (23). Further, aberrant expression of the ␣ v ␤ 3 vitronectin receptor has been demonstrated in several clinical settings associated with infertility (6 -8, 32) . Complementary expression of integrins on embryonic epithelial cells has lead to speculation of integrin involvement in the early cell-cell adhesion events during embryo-endometrial interactions (33) (34) (35) . Although data increasingly support the use of integrins as markers of uterine receptivity, an understanding of the factors regulating their expression and their role in implantation remains incomplete. This is the first general surveys of integrin expression in an endometrial cell line compared to normal endometrial epithelium. The findings described herein reconfirm how similar these cells are to normal endometrial epithelium. These cells have several constitutively expressed integrins on their surface, including ␣ 2 ␤ 1 , ␣ 3 ␤ 1 , and ␣ 6 ␤ 4 . Aside from their expression of various integrin subunits, these cells also appear to respond appropriately to steroid hormone stimulation (12, 13) and produce other known endometrial proteins (36) . Although many cell types express similar integrins, and some integrins are present on many different cell types, it is reassuring to note that this model system so closely resembles glandular endometrial epithelium. Although endometrial adenocarcinomas generally conform to the pattern of integrins seen in normal endometrium, overall integrin expression is reduced with increasing grade of the tumor (37) . As a well differentiated cell line, Ishikawa cells have retained a more normal phenotype. Using PCR, we documented what appear to be several alternately spliced forms of the ␣ 2 -subunit. Although many integrins have been noted to have such alternative forms, this has not been previously described in the ␣ 2 -subunit, and its significance is unknown.
The endometrium appears unique, exhibiting hormonally induced integrin expression. In normal endometrial epithelium, both ␣ 1 -and ␣ 4 -subunits appear at the time of ovulation, and the former has been shown to be inducible in vitro by pretreatment with P (38) . With the exception of ␣ 4 ␤ 1 , a fibronectin receptor described in the secretory phase of normal endometrium (19, 23) , the specific complement of endometrial epithelium integrins is expressed in toto by Ishikawa cells. The ␣ 4 ␤ 1 -integrin may serve to bind to the alternatively spliced form of fetal fibronectin (19) , although its role in implantation remains poorly understood. Based on these studies, we may now begin to better understand the basis for the cycle-dependent expression of ␣ 1 ␤ 1 and ␣ v ␤ 3 in the endometrial epithelial cells.
There is little doubt that P is required for the successful establishment of pregnancy. We (39) and others (40, 41) have shown that the fall in epithelial PR temporally corresponds Using flow cytometry, the relative change in median fluorescence for the ␤ 3 -integrin subunit was studied in cells treated with E 2 or E 2 plus P for 4 days (A). This decrease in ␤ 3 expression was reversed by addition of the antiprogestin, RU-486 (10 Ϫ6 mol/L). No effect was noted when Ishikawa cells were treated with P alone, suggesting that E 2 priming to induce P receptors was a prerequisite to this effect. These data were confirmed by immunoblot analysis using the SSA6 antibody, specific for the ␤ 3 -subunit (B). Ishikawa cells that received no steroid treatment expressed the ␤ 3 -integrin subunit; this was decreased by E 2 and E 2 plus P, but not by E 2 plus P plus the antiprogestin, RU486.
to the time of implantation and the appearance of the ␣ v ␤ 3 -integrin on endometrial epithelium (8, 42) . Unlike the ␣ 1 -subunit, which is induced by P at the time of ovulation, the ␣ v ␤ 3 -integrin appears to be a P-suppressed protein. The loss of PR may signal a transition from epithelial-mediated events to a stromal-dominant period, coincident with the later events of implantation. This concept is supported by recent immunohistochemical studies on endometrium from women with histologic delay and ␣ v ␤ 3 expression (42) . In that study, endometria from patients with luteal phase defect and aberrant integrin fail to down-regulate their epithelial PR in a timely fashion. After successful treatment with exogenous P or the antiestrogen clomiphene citrate to restore normal "in phase" histology, we noted the appropriate decline in PR and the concomitant return of ␣ v ␤ 3 expression. Provocative new data using the promoter for the ␤ 3 -subunit in a CAT reporter gene construct also supports this relationship between steroids and ␤ 3 gene suppression, which demonstrates that ␤ 3 appears to normally be suppressed in the endometrium by the sex steroids (43).
In Ishikawa cells, the observed changes in integrins are consonant with the hypothesis that both ␣ 1 -and ␤ 3 -subunits are coregulated by P. In the former case, ␣ 1 is stimulated by the addition of P to E 2 -primed Ishikawa cells. Further, this P-mediated event is inhibited by addition of the antiprogestin, RU-486 and is augmented by extending the time of E 2 treatment. The Ishikawa cells maintain a basal level of ␣ v ␤ 3 expression. The inhibition of this integrin by P was also dependent on priming with E 2 and is consistent with the shifts in ␣ v ␤ 3 -integrin in vivo. In the proliferative and early secretory phases, epithelial ␣ v ␤ 3 is absent, whereas epithelial PR and serum P are both elevated. In Ishikawa cells, E 2 and P mimic the early secretory phase, and addition of the antiprogestin, RU-486, mimics the midsecretory phase, when ␣ v ␤ 3 first appears. In normal endometrium this is due to the down-regulation of PR; in Ishikawa cells, this is due to blockade of this receptor. These data demonstrate the usefulness of such models to study hormonally regulated events in the endometrium.
In conclusion, we have studied expression of the ␤ 1 -and ␤ 3 -integrin family in the well differentiated Ishikawa endometrial cancer cell line. As previously demonstrated, these cells maintain both ER and PR (9), with inducible PR identical to normal endometrial epithelium (13) . Ishikawa cells express similar complement of integrins as their normal epithelial counterpart. The ␣ 2 -integrin appears to exist in this cells line in alternatively spliced forms. Like normal endometrial epithelium, cycle-specific expression of ␣ 1 and ␤ 3 also appears intact. These studies provide objective evidence that the ␤ 3 -subunit of the ␣ v ␤ 3 vitronectin receptor is a P-suppressed protein and confirms that ␣ 1 expression is stimulated by P. The Ishikawa endometrial adenocarcinoma cell line is an excellent model system for the study of steroid-mediated events and the cellular mechanisms that are important to the establishment of a receptive endometrium for implantation.
